The clinical course and outcome of COVID-19 are highly variable, ranging from
asymptomatic infections to severe disease and death. Understanding the risk factors of …

The impact of coronavirus disease 2019 (COVID-19) pandemic on patients with
neurodegenerative diseases and the specific neurological manifestations of COVID-19 have …

Background Recent numerous epidemiology and clinical association studies reported that
ApoE polymorphism might be associated with the risk and severity of coronavirus disease …

Numerous investigations have demonstrated significant and long-lasting neurological
manifestations of COVID-19. It has been suggested that as many as four out of five patients …

Alzheimer's disease (AD) and COVID-19 share many common risk factors, such as
advanced age, complications, APOE genotype, etc. Epidemiological studies have also …

Apolipoprotein E (ApoE) is a multifunctional protein critical for lipid metabolism and
cholesterol homeostasis. In addition to being a well-known genetic determinant of both …

Currently, there exists a limited comprehension regarding the correlation between COVID-
19 and Alzheimer's disease (AD). To elucidate the interrelationship and its impact on …

Background The neurological effects of the coronavirus disease of 2019 (COVID-19) raise
concerns about potential long-term consequences, such as an increased risk of Alzheimer's …

COVID-19 is an ongoing global pandemic caused by the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) virus. Although it primarily attacks the respiratory tract …

Although no longer considered a public health threat, post‐COVID cognitive syndrome
continues to impact on a considerable proportion of individuals who were infected with …